Skip to main content
OpenTrials
Completed

NCT Number: NCT06783088

Quantification With Lutetium-177 on Cadmium-Zinc-Telluride Camera 3D

The main of this study is to demonstrate the feasibility of carrying out quantitative acquisitions regardless of the energy peak considered (113 keV (kiloelectronVolts) or 208 keV or a combination of the 2 energy peaks). A study on phantom will optimise the reconstruction parameters. These parameters will then be applied to a population of patients who have already benefited from a recording on a 3D CZT camera (retrospective data).

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–99 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Chru Nancy

Vandœuvre-lès-Nancy, 54511, France

About this study

Lutetium 177 is a beta emitter - and is used in therapy. It also emits during its radioactive decay, two gamma photons of energy 113 and 208 keV allowing to produce images. The dosimetry committee of the European Association for Nuclear Medicine (EANM) recommends using only the peak at 208 keV to obtain so-called quantitative images using a conventional camera also called an Anger camera.

For several years, new semiconductor cameras (CZT cameras) have been available in nuclear medicine departments. They offer better performances particularly in terms of detection sensitivity and energy resolution. The nuclear medicine team has already carried out studies with Lutetium-177 with these semiconductor cameras on phantoms as well as dosimetry studies after treatment using Lutetium-177.

This study should demonstrate the feasibility of carrying out quantitative acquisitions regardless of the energy peak considered (113 keV or 208 keV or a combination of the 2 energy peaks). A study on phantom will optimise the reconstruction parameters. These parameters will then be applied to a population of patients who have already benefited from a recording on a 3D CZT camera (Retrospective data).

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

It is a retrospective study and the criteria to collect the imaging are:

Inclusion criteria

Patients treated by at least one cure of lutetium vipivotide tetraxetan with imaging

Exclusion criteria

Patient having sent an objection to the use of their data

Treatment and study plan

Primary outcomes

  1. Demonstrate that the quantification of images obtained with the 113 keV peak is equivalent to the quantification obtained with the 208 keV peak.

    Time frame: one day

    Measurement of contrast coefficients and metabolic volumes on reconstructed images

Sponsors and collaborators

Lead sponsor

Central Hospital, Nancy, France

Other

Registry information

Acronym: QUADO

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jan 20, 2025
Registry last updated
Dec 23, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.